PAN EBOLA VACCINE INNOVATIVE APPROACH – Sofia ref.: 116088

Project Information

PEVIA

Grant agreement ID: 116088

DOI 10.3030/116088

Project terminated on 26 April 2021

EC signature date 31 May 2017

Start date 1 June 2017

End date 31 May 2023

Funded under

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Total cost € 17 731 397,75

EU contribution € 6 189 570,00

Coordinated by

ASSISTANCE PUBLIQUE HOPITAUX DE PARIS
France

Publications

Peer reviewed articles (1)

Large-scale mapping of the Ebola NP and GP proteins reveals multiple immunoprevalent and conserved CD4 T-cell epitopes

Author(s): Yann Gallais, Raphaël Sierocki, Gautier Lhomme, Coline Sivelle, Divor Kiseljak, Florian Wurm, Sami Djoulah, Ahmed Bouzidi, Jérôme Kerzerho, Bernard Maillère
Published in: Cellular & Molecular Immunology, Issue 18/5, 2021, Page(s) 1323-1325, ISSN 1672-7681
Publisher: Nature Publishing Group
DOI: 10.1038/s41423-020-0455-2

Intellectual Property Rights

Patent (4)

MELANGES D’EPITOPES T CD8 IMMUNOGÈNES DU VIRUS EBOLA

Application/Publication number: FR 1906048
Date: 2019-06-06

PEPTIDES IMMUNOGÈNES ISSUS DE LA NUCLÉOPROTÉINE DU VIRUS EBOLA

Application/Publication number: FR 1900281
Date: 2019-01-11

PEPTIDES IMMUNOGÈNES ISSUS DE LA NUCLÉOPROTÉINE DU VIRUS EBOLA

Application/Publication number: FR 1900281
Date: 2019-01-11

MELANGES D’EPITOPES T CD8 IMMUNOGÈNES DU VIRUS EBOLA

Application/Publication number: FR 1906048
Date: 2019-06-06